Actualización en detección precoz del cáncer de próstata

IF 0.2 Q4 MEDICINE, GENERAL & INTERNAL Revista Medica Clinica Las Condes Pub Date : 2024-03-01 DOI:10.1016/j.rmclc.2024.02.001

Pablo A. Rojas , Benjamín García-Bloj , Enrique Elias , Fernando Marchant

{"title":"Actualización en detección precoz del cáncer de próstata","authors":"Pablo A. Rojas , Benjamín García-Bloj , Enrique Elias , Fernando Marchant","doi":"10.1016/j.rmclc.2024.02.001","DOIUrl":null,"url":null,"abstract":"<div><p>Prostate cancer (PCa) is the most frequent cancer in men in Chile and ranks fourth with regards to mortality according to the latest Globocan 2022 statistics. The aim of this review is to clarify what methods exist for preventing PCa, as well as updating screening recommendations based on the latest available evidence. Numerous risk factors have been described for PCa, including non-modifiable factors such as age, race, and family history. In this context, PCa screening becomes more relevant. Despite certain controversy regarding the usefulness of prostate-specific antigen (PSA), screening has shown that it increases the diagnosis of PCa in early stages, reducing mortality by up to 30%. The object of this review is to comment on the known risk factors for PCa and the usefulness of PCa screening, considering the use of new tools such as magnetic resonance imaging in the diagnosis of the disease.</p></div>","PeriodicalId":31544,"journal":{"name":"Revista Medica Clinica Las Condes","volume":"35 2","pages":"Pages 88-94"},"PeriodicalIF":0.2000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0716864024000142/pdfft?md5=768b6c02221fb0f29ef24cbd328ba11d&pid=1-s2.0-S0716864024000142-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Medica Clinica Las Condes","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0716864024000142","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Prostate cancer (PCa) is the most frequent cancer in men in Chile and ranks fourth with regards to mortality according to the latest Globocan 2022 statistics. The aim of this review is to clarify what methods exist for preventing PCa, as well as updating screening recommendations based on the latest available evidence. Numerous risk factors have been described for PCa, including non-modifiable factors such as age, race, and family history. In this context, PCa screening becomes more relevant. Despite certain controversy regarding the usefulness of prostate-specific antigen (PSA), screening has shown that it increases the diagnosis of PCa in early stages, reducing mortality by up to 30%. The object of this review is to comment on the known risk factors for PCa and the usefulness of PCa screening, considering the use of new tools such as magnetic resonance imaging in the diagnosis of the disease.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

前列腺癌早期检测的最新进展

前列腺癌（PCa）是智利男性最常见的癌症，根据 2022 年全球前列腺癌协会（Globocan）的最新统计数据，其死亡率在智利男性癌症中排名第四。本综述旨在阐明预防前列腺癌的方法，并根据现有的最新证据更新筛查建议。PCa 的风险因素众多，包括年龄、种族和家族史等不可改变的因素。在这种情况下，PCa 筛查变得更加重要。尽管对前列腺特异性抗原（PSA）的作用存在一定争议，但筛查结果表明，它能提高 PCa 早期诊断率，最多可降低 30% 的死亡率。本综述旨在对 PCa 的已知风险因素和 PCa 筛查的实用性进行评论，同时考虑到磁共振成像等新工具在疾病诊断中的应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊